American Academy of Family Physicians

Printer-friendly version

Share this on AAFP Connection

Share this page

'Shangai' Products Are Case in Point

NCCAM Materials Can Help You Discuss CAM With Patients

By News Staff

A recent FDA advisory about dietary supplements from China that are considered illegal illustrates why it's important for physicians and patients to discuss complementary and alternative medicine, or CAM. To encourage such discussions, the National Center for Complementary and Alternative Medicine, or NCCAM, is offering free materials for doctors and consumers through its "Time to Talk" campaign.

Graphic for NCCAM's Time to Talk initiative
The Dec. 28 FDA advisory warns patients to avoid certain products from China that are labeled as dietary supplements but that contain sildenafil, the active ingredient in prescription drugs for erectile dysfunction, known as ED, or a specific sildenafil analog. Neither ingredient is listed on the product labels.

The products listed in the FDA advisory are Super Shangai; Strong Testis; Shangai Ultra; Shangai Ultra X; Lady Shangai; and Shangai Regular, also marketed as Shangai Chaojimengnan. They have been marketed for the treatment of ED and for sexual enhancement.

According to the advisory, the products are illegal drugs because they lack FDA approval.

Advisory Warns of Drug Interactions

The advisory specifically targets patients with diabetes, high blood pressure, high cholesterol or heart disease, who often take nitrate-containing prescription medications such as nitroglycerin to control their symptoms. According to the advisory, ED is common among men with these conditions, yet sildenafil and its analogs can interact with nitrates, resulting in dangerously low blood pressure levels.

Because men who use nitrates for these health conditions may have been advised to not take ED drugs, "they may seek out products like these because they are marketed as 'all natural' or as not containing the active ingredients in approved, prescribed ED drugs," says the advisory.

Kits Can Help Trigger CAM Discussion

Physicians who discuss CAM with their patients are more likely to know which patients might try such supplements, but doctors need to do a better job of initiating CAM discussions, according to a recent AARP/NCCAM survey of Americans 50 and older.

Almost two-thirds of survey respondents reported they had used one or more CAM therapies, but fewer than one-third of those respondents said they had discussed their CAM use with their physicians. The top reason cited was that the doctor never asked (42 percent).

To encourage CAM discussions, NCCAM offers a free toolkit containing educational materials for physicians, their staff members and their patients. The kit includes a backgrounder; posters; tips for discussing CAM; and a patient wallet card for tracking medications, including CAM therapies. A "patient packet" is available as well. Both items may be ordered online or from the NCCAM Clearinghouse at (888) 644-6226. When ordering by phone, use reference code D392 for the health care professional toolkit; use code D393 when ordering the patient packet.

In general, NCCAM offers these CAM discussion tips for physicians:
  • Include a question about CAM use on medical history forms.
  • Ask patients to bring a list of all therapies they use, including prescription, over-the-counter and herbal products, and other CAM practices.
  • Have medical staff, such as nurses or physician assistants, initiate the conversation.
More information about "Time to Talk" is available online.

Share this on AAFP Connection

Health of the Public

Study: PPI Does Not Routinely Improve Asthma Control

Recalled Oral Contraceptives Pose Pregnancy Risk

CDC to Fund 2D Vaccine Barcoding Pilot

2012 Immunization Schedules Reflect Multiple Changes

Study: Cognitive Decline Detected in Middle-aged Adults

CDC Toolkit Can Help Clinicians Fight Norovirus Infection

Patient-Centered Care Linked to Lower Mortality

Study: Inappropriate Cancer Screenings Continue

Novartis Manufacturing Plant Closes After Drug Mix-ups

FDA Announces Classwide REMS for TIRF Medications

New Infants' Acetaminophen Products Hit Store Shelves

Avoid Environmental Factors Linked to Breast Cancer

Risk for Thrombosis Prompts REMS for Rivaroxaban

Common Drugs Implicated in Most Emergency Hospitalizations

CDC Launches Campaign for Child Medication Safety

HHS Blocks Expanded OTC Access to Plan B

Push Is On to Vaccinate Pregnant, Postpartum Women

FDA Committee Votes to Broaden PCV13 Indication

AAFP Foundation Program Aims to Fight Chronic Disease

NIAAA Alcohol Screening Guide Targets Teens

Walgreens, AAFP Launch Flu Vaccine Pilot in Five States

Helping Patients Quit Smoking Starts With a Question

Trilipix Efficacy in Question, Says FDA

USPSTF Addresses Skin Cancer, Obesity, Cervical Cancer Screening

AAFP Endorses ACP Guideline on ED

ACIP Recommends Expanded HPV, Hepatitis B Vaccination

Bacterial Contamination Spurs Nasal Spray Recall

CDC Renews Call for PCV13 Vaccination

USPSTF Recommends Against PSA Screening

AAFP Supports HHS' Million Hearts Initiative

FDA Phases Out Primatene Mist Inhalers

AHRQ Guides Explain Benefits, Risks of GERD Treatments

Tar Wars Winner Gives Back

Office Champions Project Nets Smoking Cessation Gains

Multiple Lots of Oral Contraceptives Recalled

New Vaccine Review Finds Few Adverse Events

HPV Vaccination Rates Still Lag, Says CDC

Renal Injury Prompts Reclast Label Changes

High-dose Citalopram Linked to Abnormal Heart Rhythms

AHRQ Sleep Apnea Guides Review Diagnosis, Management

Board Chair Spotlights Breadth of Family Medicine Training

USPSTF Softens Stance on Bladder Cancer Screening

HHS Expands Coverage for Women's Preventive Services

Teledermatology Project Aids Underserved Patients

New Chantix Warnings Cite Cardiovascular Risk

Pertussis Outbreaks Lead to CDC Alert on PCR Testing